presentation will be to build on the information and assess whetherand how a CGA should be used in clinic and research. We willstructure the presentation along the lines of: What are the knownand established points that are ready for clinical use; what are thepoints were evidence can be used in a more limited fashion; andwhat is still in the domain of research.

doi:10.1016/j.jgo.2013.09.243

Thomas FlaigMedicine (Medical Oncology), University of Colorado, Aurora,United StatesThomas Flaig, MD, is a medical oncologist and Associate Professor ofMedicine at the University of Colorado in Denver, USA. He attendedmedical school at the University of Minnesota and residency at theHennepin County Medical Center in Minneapolis, before moving tothe University of Colorado in 2003. He also currently serves as theMedical Director of the University of Colorado Cancer Center’sClinical Trials Office.Dr. Flaig’s focus is on urologic cancers; he has been the localPrincipal Investigator of numerous prostate, bladder and kidneycancer therapeutic trials. He has recently published in the field inthe New England Journal of Medicine, Journal of Clinical Oncology,British Journal of Cancer and Nature Reviews in Clinical Oncology.

doi:10.1016/j.jgo.2013.09.244

Claire FalandryGeriatrics, Centre Hospitalier Lyon Sud, Pierre-Benite CedexLyon University, Lyon, FranceClaire Falandry, MD, PhD is currently an hospital and facultypractitioner in the Geriatric Unit of Lyon Sud Hospital, Pierre-Benite,France. She did her medical internship in Lyon, France, and got aspecialization in oncology in 2006 and in geriatrics in 2008. She wasAssistant Professor in the Oncology Department of Lyon Sud Hospitalheaded by Pr V. Trillet-Lenoir from 2006 to 2010. She is graduated inMolecular Biology with a PhD obtained in 2008 in Pr E. Gilson’slaboratory “Epigenetic and telomeric regulations”. She acquired apost-doctoral experience in the Institute of Molecular Medicine andMax Planck Department on Stem Cell Aging headed by Pr K.L.Rudolph in 2010-2011. She was the scientific coordinator of severaltrials of the GINECO (Groupe d’Investigateurs Nationaux pour l’Etudedes Cancers de l’Ovaire et du sein, a French collaborative group ofinvestigators) dedicated in the analyses of the impact of geriatriccovariates on the outcome of elderly (≥70) patients treated forbreast or ovarian cancer.

doi:10.1016/j.jgo.2013.09.245

Djamel GhebriouMedical Oncology, Centre Hospitalier Argenteuil, Argenteuil, FranceDjamel Ghebriou is a medical doctor within the Inter-Hospital OncologyFederationArgenteuil-Eaubonne in the suburbs of Paris (France), and is incharge of geriatric oncology. He is the president of the FRancilianOncoGeriatric Group (FROG) which is a training and research group ingeriatric oncology based in the Paris region.

doi:10.1016/j.jgo.2013.09.246

Paul HamlinSalvage therapy, and new agents and stem cell transplant in the olderpatient with recurrent diffuse large B-cell lymphoma, New York, UnitedStatesPaul A. Hamlin, MD is an Assistant Member Physician on theLymphoma Service at Memorial Sloan-Kettering Cancer Center inthe Division of Hematologic Oncology and an Assistant Professor ofMedicine at Weill Medical College of Cornell University MedicalCollege in New York. He is the Director of Outpatient Clinicalactivities and Innovation Lab for the Lymphoma service at MSKCC.Dr. Hamlin received his undergraduate degree from Duke University,NC before returning to his home state of New York, where hereceived his medical degree from the State University of New YorkHealth Sciences Center at Brooklyn, graduating Magne Cum Laudeand a member of the AOA society. His postgraduate training includedan internship and residency at New York University Hospital and afellowship in medical oncology and hematology at Memorial Sloan-Kettering Cancer Center, where he served as Chief Fellow from 2001-2002. He is certified by the American Board of Internal Medicine andholds subspecialty certification in Medical Oncology.Dr. Hamlin’s clinical area of expertise is in the treatment ofHodgkin’s and Non-Hodgkin’s Lymphomas. He has specialized inthe care of older patients with lymphoma, working in amultidisciplinary team to develop new treatment strategiesand clinical trials specifically aimed at this patient population.His research interests include novel biologic and immunother-apeutic agents for the treatment of hematologic malignancies,with ongoing work in novel agents, small molecule inhibitors,monoclonal antibodies and radio-immunotherapy. Additionally,he is investigating predictive models for toxicity using geriatricassessment the patient's undergoing chemotherapy for lympho-ma. He has published articles and abstracts in such journals asAnnals of Oncology, British Journal of Hematology, Journal ofClinical Oncology and Blood. In addition to serving as a peerreviewer for a number of prominent journals, Dr. Hamlin ishighly involved in clinical research as principal investigator andlectures worldwide. He is a member of several professionalorganizations including the American Society of Clinical Oncol-ogists and the American Society of Hematology.

doi:10.1016/j.jgo.2013.09.247

Jørn HerrstedtOncology, Odense University Hospital, Odense, DenmarkEducationM.D. University of Copenhagen 1983.· Specialist in Internal Medicine 1997.· Doctor Medicinae, University of Copenhagen 1998.Position· Chief Consultant and Professor in Clinical Oncology, Department ofOncology, Odense University Hospital, Denmark and the Universityof Southern Denmark.Publications· Doctoral thesis: "Chemotherapy-induced nausea and vomiting withspecial emphasis on metopimazine" University of Copenhagen 1998.· 108 published papers including 84 peer-reviewed papers. 1. authoron 45 and senior author on 17 publications.Member International Working Groups· Coordinator of ESMO Faculty on Supportive and Palliative Care(present)· Clinical Trials Unit, Nordic Society for Gynecologic Oncology –

NSGO (present).· Steering Committee MASCC and ESMO antiemetic guidelines group(present).

2013 SIOG Speaker Biographies S3